Luke Engelking, M.D., Ph.D.

Luke Engelking, M.D., Ph.D.

  • Internal Medicine - Digestive and Liver Diseases
  • Inherited GI Cancer Syndromes
  • Polyposis Syndromes


Download Curriculum Vitae

Luke Engelking, M.D., Ph.D., is an Associate Professor of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Digestive and Liver Diseases. His clinical interests include the treatment of patients with either known or suspected inherited disorders of polyposis and colorectal cancer, including Lynch syndrome, Familial Adenomatous Polyposis syndrome, Peutz-Jeghers syndrome, Juvenile Polyposis syndrome, and Cowden syndrome.

Originally from Houston, Dr. Engelking received bachelor's degrees in biochemistry and genetics from Texas A&M University. He then completed his medical degree and a doctoral degree in biomedical science at UT Southwestern, where he studied cholesterol and fat metabolism under the tutelage of Michael Brown, M.D., and Joseph Goldstein, M.D. He obtained internal medicine residency training at Massachusetts General Hospital in Boston, and returned to UT Southwestern for clinical and research fellowships in gastroenterology.

As a postdoctoral researcher, he studied lipid synthesis in the intestine, which is recognized as a key metabolic organ at the center of nutrient homeostasis. He demonstrated that Sterol Response Element-Binding Proteins (SREBPs) are major players in the regulation of intestinal lipid synthesis.

A Diplomate of the American Board of Internal Medicine in both internal medicine and gastroenterology, Dr. Engelking joined the UT Southwestern faculty in 2014.

After establishing his research laboratory, he began investigating the molecular underlying lipid regulation of intestinal epithelial homeostasis and tumorgenesis, supported by a K08 award (2014-2020) and currently by an R01 award (2019-2024) from the National Institute of Diabetes and Digestive and Kidney Diseases, as well as an individual investigator research award (R01 equivalent) grant from Cancer Prevention & Research Institute of Texas (CPRIT). His ultimate goals are to discover new lipid-derived oncometabolites that may be targeted in the fight against colon cancer, and to clarify the links between dietary lipids and intestinal cancers.

Dr. Engelking is an active member of the American Society for Biochemistry and Molecular Biology, and the American Gastroenterological Association.

Education & Training
  • Fellowship - UT Southwestern Medical Center (2010-2014), Gastroenterology
  • Residency - Massachusetts General Hospital (2007-2010), Internal Medicine
  • Medical School - UT Southwestern Medical School (2000-2007)
Professional Associations & Affiliations
  • American Society for Biochemistry and Molecular Biology (2014)
  • American Gastroenterological Association (2010), Member
Honors & Awards
  • Disease-Oriented Clinical Scholar Award, UT Southwestern 2015
  • Research Scholar in Liver Disease, North American Gilead Sciences 2014
  • Distinguished Researcher's Award,UT Southwestern President's Research Council 2014
  • Alpha Omega Alpha, UT Southwestern Medical School 2007
  • University Honors, Texas A&M University 2000
Books & Publications
  • SREBP, Scap and Insig Proteins
  • Enteroendocrine Cell Biology
  • Cholesterol and Fat Metabolism

Clinical Focus

  • Inherited GI Cancer Syndromes
  • Polyposis Syndromes
  • Familial Adenomatous Polyposis Syndrome
  • Lynch Syndrome
  • Rare and Genetic Disorders of the GI Tract

See More